{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-25-000002","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.433871+00:00","generated_at":"2026-05-28T03:32:49.070876+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna: 2024 sales $3.0-3.1B; 2025 revenue guided $1.5-2.5B, down ~40%; CMV trial misses early efficacy","bullets":["2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.","2025 revenue guidance $1.5-2.5B (mostly H2); expects year-end cash ~$6.0B.","Accelerating cost cuts: $1B cash-cost reduction in 2025, additional $0.5B in 2026.","CMV vaccine Phase 3 DSMB: early efficacy not met; study continues blinded. Final data expected 2025.","Next-gen COVID BLA accepted (PDUFA May 31, 2025); RSV vaccine for high-risk adults filed; flu/COVID combo filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-25-000002","json":"https://secwatch.observer/filing/0001682852-25-000002.json","markdown":"https://secwatch.observer/filing/0001682852-25-000002.md","text":"https://secwatch.observer/filing/0001682852-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/0001682852-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/mrna-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:32:49.070876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}